Mizuho raised the firm’s price target on GE HealthCare to $92 from $90 and keeps a Buy rating on the shares. The analyst sees a favorable sentiment setup heading into the Q1 results for medtech and diagnostics companies. A sentiment shift is being driven by a steadily improving procedure volume backdrop coupled with less idiosyncratic risk versus other healthcare sub-sectors, the analyst tells investors in a research note. These themes are coupled with a favorable Q1 setup where the combination of conservative guides from earlier in the year against omicron headwinds last year has set up a "low bar" for many names into this upcoming earnings cycle, says the firm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GEHC:
- GE HealthCare initiated with a Neutral at BTIG
- ICU teams with Linden Capital for Medtronic assets bid, Reuters reports
- GE HealthCare initiated with an Outperform at Evercore ISI
- GE HealthCare stock had a great start, more gains lie ahead, Barron’s says
- General Electric price target raised to $96 at BofA ahead of investor day